Financial Performance - Revenue for the six months ended June 30, 2025, was HK$51,060,000, a decrease of 16.2% compared to HK$60,932,000 for the same period in 2024[5] - Gross profit for the period was HK$16,533,000, down 15.4% from HK$19,661,000 in the previous year[5] - Profit before income tax was HK$1,532,000, a significant recovery from a loss of HK$28,834,000 in the same period last year[5] - Profit for the period attributable to owners of the Company was HK$1,418,000, compared to a loss of HK$28,663,000 in the prior year[6] - Total comprehensive income for the period was HK$1,419,000, a turnaround from a loss of HK$28,660,000 in the previous year[6] - The consolidated profit before income tax for the six months ended June 30, 2025, was HK$1,532,000, a significant improvement from a loss of HK$28,834,000 in 2024[41] - The Group recorded a profit attributable to owners of approximately HK$1 million, a turnaround from a loss of approximately HK$29 million in the corresponding period, primarily due to a reversal of impairment loss of approximately HK$3 million and a reduction in general and administrative expenses from approximately HK$18 million to HK$8 million[165] Cash Flow and Liquidity - Cash and cash equivalents at the end of the period decreased to HK$4,366,000 from HK$7,005,000 at the end of June 2024[11] - Net cash used in operating activities was HK$347,000, an improvement from HK$2,556,000 used in the same period last year[11] - The cash flow projections indicate that the Group expects to have sufficient working capital to meet its financial obligations over the next twelve months[19] - The Directors are implementing measures to improve cash flow, including actively collecting loan receivables and reviewing investments for potential liquidation[18] Assets and Liabilities - Current liabilities decreased to HK$56,877,000 from HK$72,998,000 at the end of December 2024[8] - Non-current liabilities increased to HK$70,986,000 from HK$67,428,000 at the end of December 2024[9] - As of June 30, 2025, the Group reported net liabilities of HK$16,961,000, indicating a significant financial challenge[15] - The Group's accumulated losses decreased from HK$77,311,000 as of June 30, 2024, to HK$67,676,000 as of June 30, 2025, reflecting an improvement in financial performance[12] - Total consolidated assets fell from HK$122,046,000 at 31 December 2024 to HK$110,902,000 at 30 June 2025, representing a decrease of 9.1%[44] - Total consolidated liabilities decreased from HK$140,426,000 at 31 December 2024 to HK$127,863,000 at 30 June 2025, a decline of 8.9%[46] Revenue Segments - Revenue from the sale of Chinese health products for the six months ended June 30, 2025, was HK$50,975,000, a decrease of 15.5% compared to HK$60,426,000 for the same period in 2024[30] - Revenue from Hong Kong operations decreased from HK$60,932,000 for the six months ended 30 June 2024 to HK$51,060,000 for the same period in 2025, a drop of 16.3%[50] - The Chinese health products segment generated revenue of approximately HK$51 million, a decrease from HK$60 million in 2024, and reported a segment loss (before taxation) of approximately HK$4 million, compared to a loss of HK$2 million in 2024[164] Expenses and Costs - General and administrative expenses decreased significantly from approximately HK$18 million in the corresponding period to approximately HK$8 million during the period due to cost-saving measures[156] - Finance costs increased to approximately HK$7 million for the six months ended June 30, 2025, from approximately HK$5 million in the corresponding period, primarily due to a higher effective interest rate on borrowings[157] - Selling and distribution expenses remained stable at approximately HK$14 million, compared to approximately HK$15 million in the corresponding period, reflecting effective cost-control measures[150] Impairment and Credit Losses - A reversal of impairment loss of approximately HK$3 million was recognized for the Group's loan receivables during the period, compared to an impairment loss of approximately HK$6 million in the corresponding period[158] - The accumulated allowance for expected credit loss (ECL) on loan receivables decreased from approximately HK$300 million as of December 31, 2024, to approximately HK$297 million as of June 30, 2025[175] - The impairment loss on loan receivables under the ECL model saw a reversal of approximately HK$3 million during the period, compared to an impairment loss of HK$6 million in 2024[173] Share Capital and Options - The Group's share capital remained stable at HK$7,705,000 as of June 30, 2025, with no changes reported during the period[12] - The New Share Option Scheme was adopted on August 15, 2024, following amendments to Chapter 17 of the Listing Rules effective January 1, 2023[101] - No share options were granted, exercised, lapsed, or cancelled during the periods ended June 30, 2025, and December 31, 2024[116] Market and Consumer Trends - The shift in consumer spending patterns in Hong Kong has adversely affected the Group's revenue, as consumers are increasingly opting to purchase in Mainland China[164] - The brand "Nam Pei Hong" remains highly recognized in Hong Kong and Southern Mainland China, with 10 retail shops as of June 30, 2025[166]
中国智能健康(00348) - 2025 - 中期财报